Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Concurrent: The jump from computing

Until recently, Concurrent Pharmaceuticals Inc. has relied on its Concentric computational platform to identify and optimize small molecule candidates to treat cardiovascular and renal diseases. However, the company has taken a big step toward a product focus by acquiring a portfolio of compounds that are in or near the clinic in

Read the full 514 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers